8 June 2020 - A Dunedin mother whose son died soon after his usual epilepsy drug was replaced by a controversial alternative medication is disappointed by a new report into drug supply agency PHARMAC’s decision-making process.

In March 2019, PHARMAC opted to use a sole supplier of the epilepsy drug lamotrigine, which meant from October patients on other brands of the drug instead had to use the sole funded option, Logem.

Almost immediately some patients reported adverse effects following the change in medication, and in December the chief coroner announced a joint inquest into several deaths linked to Logem.

Read Otago Daily News article